Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JD 001

Next Previous
Drug Profile

JD 001

Alternative Names: JD-001

Latest Information Update: 08 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing JD Biotech
  • Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 08 Oct 2025 JD 001 is still in phase I trials for Chronic lymphocytic leukaemia (In adults, In the elderly, Refractory metastatic disease), Non-Hodgkin's lymphoma (In adults, In the elderly, Refractory metastatic disease), Precursor cell lymphoblastic leukaemia-lymphoma (In adults, In the elderly, Refractory metastatic disease) in China (IV-infusion) (NCT05739227)
  • 22 Feb 2023 Phase-I clinical trials in Chronic lymphocytic leukaemia (Refractory metastatic disease, In adults, In the elderly) in China (IV-infusion) (NCT05739227)
  • 22 Feb 2023 Phase-I clinical trials in Non-Hodgkin's lymphoma (Refractory metastatic disease, In adults, In the elderly) in China (IV-infusion) (NCT05739227)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top